Bio-key International Stock Earnings Reports

BIO-key reported strong Q1 2026 results with revenue up 34% year-over-year to $2.1M driven by expanded license renewals (notably a large banking customer) and a >100% increase in hardware sales (including sales of previously fully reserved inventory and defense-related hardware). Gross margin remained high at ~82%. Operating expenses were roughly flat quarter-over-quarter, producing an improved net loss of $165k (versus $737k a year ago). Management reiterated that the business is predominantly subscription-based with a large partner-driven go-to-market (50% domestic new business via partners; 100% international via channel partners). The company highlighted growing traction in defense, financial services and EMEA markets, new partnerships (notably DLT/TD Synnex to reach U.S. public sector customers), and favorable secular trends toward passwordless and biometric authentication. Financial position: book value $7.6M (~$7.04/share), cash ~$2.2M, current assets ~$4.5M. Management expects to file the 2025 Form 10-K imminently, to become current on filings, and is pursuing an appeal hearing (scheduled June 16, 2026) to regain Nasdaq listing; meanwhile shares trade OTC under BKYI. Management expects profitability and positive cash flow in Q2 and is focused on scaling larger, higher-margin deals through partners.